Regeneron Pharmaceuticals, Inc. $REGN Stock Purchased by Compass Financial Management LLC

Key Points

• Compass Financial Management increased its Regeneron stake by 4,526.2% in the third quarter, ending the period with 3,007 shares valued at about $2.28 million.
• Regeneron reported quarterly earnings of $20.07 per share and revenue of $5.12 billion, beating analyst estimates; revenue rose 36.3% year over year.
• Analysts’ consensus rating is “Moderate Buy,” with an average price target of $898.97. Recent insider sales were also disclosed, including transactions by company executives and directors.

Compass Financial Management LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4,526.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,007 shares of the biopharmaceutical company's stock after acquiring an additional 2,942 shares during the period. Compass Financial Management LLC's holdings in Regeneron Pharmaceuticals were worth $2,280,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Regeneron Pharmaceuticals during the second quarter worth about $5,682,636,000. State Street Corp raised its holdings in Regeneron Pharmaceuticals by 3.6% in the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company's stock valued at $3,014,621,000 after buying an additional 170,210 shares during the last quarter. Bank of America Corp DE boosted its position in Regeneron Pharmaceuticals by 8.5% during the 2nd quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company's stock worth $805,023,000 after buying an additional 101,469 shares during the period. Amundi grew its holdings in Regeneron Pharmaceuticals by 0.4% during the 2nd quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company's stock worth $631,983,000 after acquiring an additional 3,742 shares during the last quarter. Finally, Legal & General Group Plc bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $473,872,000. Institutional investors own 83.31% of the company's stock.

Insider Buying and Selling

In related news, insider Andrew J. Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider directly owned 47,833 shares in the company, valued at $36,960,559.10. This trade represents a 7.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 20,789 shares of company stock worth $18,766,698. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $930.67 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $591.52 and a 1-year high of $991.73. The business has a 50-day moving average price of $800.69 and a 200 day moving average price of $741.11. The company has a market capitalization of $95.82 billion, a P/E ratio of 20.55, a PEG ratio of 1.45 and a beta of 0.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping analysts' consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The business had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. During the same period in the previous year, the company posted $11.83 earnings per share. The firm's revenue was up 36.3% on a year-over-year basis. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 51.64 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.30%.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America added REGN to its Value 10 list, a favorable signal about the stock’s value appeal. BofA adds REGN to Value 10 list
• Positive Sentiment: Recent analyst coverage points to higher price targets and expectations for appreciation. Separately, Zacks said solid earnings-estimate revisions could help the shares continue gaining. These views follow Regeneron’s recent quarterly results, which beat consensus on earnings and revenue. RBC raises Regeneron price target Zacks on earnings estimate revisions
• Negative Sentiment: Recent disclosures show EVP Joseph Larosa sold 4,466 shares and director Christine Poon sold 7,830 shares on November 2; Poon’s sale cut her direct holding by 60%. Director Kathryn Guarini also sold 400 shares under a pre-arranged trading plan. The larger transactions could raise concerns about insider sentiment, though sales alone do not indicate a change in the company’s business outlook. Larosa sale filing Poon sale filing Guarini sale filing

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of recent research reports. Wells Fargo & Company lifted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the stock an "equal weight" rating in a report on Monday. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $779.00 to $855.00 and gave the stock an "equal weight" rating in a report on Monday. Cantor Fitzgerald upped their price target on Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the company an "overweight" rating in a research report on Monday. Robert W. Baird lifted their price objective on Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the stock a "neutral" rating in a research note on Monday. Finally, Argus upgraded Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $850.00 target price on the stock in a report on Thursday, October 1st. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $898.97.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.